Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ABBV
ABBVIE INC.
NYSE
$255.48
▼ DOWN 1.03% (-2.67)

KEY STATISTICS

Market Cap$451.38 B
52w High$267.47
52w Low$190.75
Dividend Yield2.81%
FrequencyQuarterly
P/E25.07
Volume3.22M
Shares Out.1.77B

COMPANY

LEADERSHIP

Robert A. Michael
CHIEF EXECUTIVE
Robert A. Michael

COMPENSATION 2026

Salary$1,700,000
Stock Awards$13,268,456
Incentive Plan Pay$5,200,000
All Other Comp.$516,293
Total$32,530,984

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 2, 2013
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
57,000

PRICE TARGET

Target High$303.00
Target Low$235.00
Target Median$296.00
Target Consensus$285.92

UPCOMING EARNINGS

DateOct 30, 2026
DayFriday
Rev. Est.$17.31B
OCT
30
FRI

PRICE

$255.48 ▼ DOWN 1.03% (−$2.67)
$255$256$257$2589:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM255.48

About AbbVie Inc.

https://www.abbvie.com ↗

AbbVie Inc. is a global biopharmaceutical company that develops and sells a wide range of medicines, including immunology, oncology, neuroscience, and eye care products, with a focus on innovative therapies for various diseases.

INDUSTRY

Drug Manufacturers - General

A PRODUCT ABBVIE INC. IS KNOWN FOR

Skyrizi (risankizumab)
Skyrizi (risankizumab)

AbbVie's top-selling injectable medication treats moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease, becoming the company's main growth driver after Humira's decline.

COMPETITORS

COMPETITOR
AMGN COMPARE
GILD COMPARE
JNJ COMPARE
LLY COMPARE
NVS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
SKYRIZI$4.71B $5.01B ▲$4.48B ▼$5.5B ▲
RINVOQ$2.18B $2.37B ▲$2.12B ▼$2.52B ▲
Other Products$660M $617M ▼$1.02B ▲$1.11B ▲
Vraylar$934M $1.02B ▲$905M ▼$1.07B ▲
Botox Therapeutic$985M $990M ▲$1.01B ▲$1.04B ▲
VENCLEXTA$726M $710M ▼$770M ▲$771M ▲
H U M I R A$993M $1.25B ▲$688M ▼$756M ▲
Botox Cosmetic$637M $717M ▲$668M ▼$728M ▲
Imbruvica$706M $671M ▼$556M ▼$532M ▼
Ubrelvy$354M $339M ▼$339M $392M ▲
Qulipta$288M $288M $296M ▲$350M ▲
Other Aesthetics$303M $320M ▲$286M ▼$309M ▲
LinzessConstella$326M $175M ▼$283M ▲$295M ▲
MAVYRET$312M $324M ▲$351M ▲$295M ▼
Other Eye Care$248M $294M ▲— —
Juvederm Collection$253M $249M ▼$232M ▼$245M ▲
Ozurdex$117M $128M ▲— —
Other Neuroscience$46M $47M ▲$125M ▲$117M ▼
LumiganGanfort$97M $104M ▲— —
Duodopa$96M $92M ▼— —
AlphaganCombigan$47M $54M ▲— —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$4.23B $35.16B ▲$3.77B ▼$4.77B ▲
NonUS$625M $0 ▼$714M ▲$760M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,322
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.61% · 56.3M
IHVV.AX
0.70% · 23.6M
SPY
0.68% · 21.7M
JEPI
1.64% · 2.9M
CGDV
1.54% · 2.3M
FLCO
0.37% · 2.1M
SCHX
0.65% · 1.9M
DGRW
2.09% · 1.4M
FHLC
6.24% · 848.8K
RSP
0.21% · 837.1K
XDWH.L
5.31% · 835.4K
DFAC
0.43% · 830.8K
SMOR.SW
0.78% · 769.3K
HMWD.L
1.01% · 732.6K
USMC
3.39% · 666.6K
NOBL
1.41% · 656.7K
ZSP.TO
0.69% · 550.1K
AFTY
4.95% · 400.4K
BGIG
4.01% · 349.3K
WRDUSW.SW
0.51% · 335.1K
SPYI
0.69% · 315.3K
QDF
2.95% · 293.5K
FTXH
6.94% · 287.1K
PB
PBPH
6.73% · 270.8K
GSLC
0.44% · 258.7K
NULV
1.87% · 209.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
48.03%
HOLDERS
5,284
TOP 12 OF 5,284 · RANKED BY POSITION SIZE
Vanguard Group Inc
180.8M sh · $41.31B
Blackrock, Inc.
151.2M sh · $34.54B
Blackrock Inc.
136.4M sh · $23.4B
State Street Corp
82.6M sh · $20.78B
Jpmorgan Chase & Co
56.7M sh · $12.09B
Geode Capital Management, LLC
47.0M sh · $11.81B
Blackrock Institutional Trust Company, N.A.
43.5M sh · $2.72B
Morgan Stanley
41.7M sh · $9.64B
Capital Research Global Investors
31.3M sh · $6.8B
Charles Schwab Investment Management Inc
26.0M sh · $6.01B
Bank Of America Corp /De/
25.8M sh · $5.9B
Norges Bank
25.7M sh · $5.87B

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets4
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Josh Gottheimer
Josh Gottheimer
Sale
2026-05-05
 Julie Johnson
Julie Johnson
Sale
2025-12-18
 Julia Letlow
Julia Letlow
Sale (Full)
2025-12-08
 Lisa McClain
Lisa McClain
Sale
2025-10-31

INSIDER TRADES

★
OFFICER: EVP, CHIEF BUS/STRAT OFFICER
Donoghoe Nicholas
Sale · 32.7K shares
2026-08-14
★
OFFICER: EVP, CHIEF BUS/STRAT OFFICER
Donoghoe Nicholas
Purchase · 32.7K shares
2026-08-14
★
DIRECTOR
RAPP EDWARD J
Purchase · 134 shares
2026-06-30
★
DIRECTOR
Quaggin Susan E
Purchase · 62 shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 6
BUY 6
OUTPERFORM 5
NEUTRAL 3
20 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Wells Fargo OVERWEIGHT Wolfe Research OUTPERFORM BNP Paribas NEUTRAL Evercore ISI Group OUTPERFORM Guggenheim BUY Cantor Fitzgerald OVERWEIGHT Canaccord Genuity BUY

SECTORS PEERS

PEERPRICE
JNJ$268.04COMPARE
MRK$148.26COMPARE
UNH$392.95COMPARE
NVS$153.81COMPARE
AZN$162.70COMPARE
AMGN$432.42COMPARE
NVO$45.61COMPARE
GILD$145.68COMPARE